Author

Nancy Poorvu

Institutions: Harvard University, Dana-Farber Cancer Institute

Observed institutions: Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute

ORCID: 0000-0002-4047-0299

Observed ORCID: 0000-0002-4047-0299

OpenAlex ID: A5016453396

Extrapolation of ACOSOG Z0011 trial results—A survey of breast cancer providers

2021 · Anna Weiss, Victoria Cooley, et al. · The Breast Journal · 6

Supplementary Tables and Figures S1 from Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2− Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial

2026 · Adrienne G. Waks, Elia Segui, et al.

Data from Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2− Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial

2026 · Adrienne G. Waks, Elia Segui, et al.

Protocol 1 from Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2− Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial

2026 · Adrienne G. Waks, Elia Segui, et al.

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2− Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial

2026 · Adrienne G. Waks, Elia Segui, et al. · Clinical Cancer Research

Abstract CT028: A single-arm phase 1 trial of avutometinib (RAF/MEK inhibitor), abemaciclib (abema), and fulvestrant in CDK4/6 inhibitor (CDK4/6i)-pretreated patients (pts) with HR+ metastatic breast cancer (MBC)

2025 · Adrienne G. Waks, Elia Segui, et al. · Cancer Research

Works count: 6

Citation count: 6

H-index: 1

I10-index: